Chronic Cough

COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of COUGH-1 and -2, looking at gefapixant efficacy by patient history of refractory […]

With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss the current unmet needs when treating chronic cough and the investigational P2X3 receptor antagonists currently in […]

Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant. […]

We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]

Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]